MYC regulation of a "poor-prognosis" metastatic cancer cell state
Author(s)
Mesirov, Jill P.; Wolfer, Anita; Wittner, Ben S.; Irimia, Daniel; Flavin, Richard J.; Lupien, Mathieu; Gunawardane, Ruwanthi N.; Meyer, Clifford A.; Lightcap, Eric S.; Tamayo, Pablo; Liu, X. Shirley; Shioda, Toshi; Toner, Mehmet; Loda, Massimo; Brown, Myles; Brugge, Joan S.; Ramaswamy, Sridhar; ... Show more Show less
DownloadWolfer_MYC regulation.pdf (951.3Kb)
PUBLISHER_POLICY
Publisher Policy
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Terms of use
Metadata
Show full item recordAbstract
Gene expression signatures are used in the clinic as prognostic tools to determine the risk of individual patients with localized breast tumors developing distant metastasis. We lack a clear understanding, however, of whether these correlative biomarkers link to a common biological network that regulates metastasis. We find that the c-MYC oncoprotein coordinately regulates the expression of 13 different “poor-outcome” cancer signatures. In addition, functional inactivation of MYC in human breast cancer cells specifically inhibits distant metastasis in vivo and invasive behavior in vitro of these cells. These results suggest that MYC oncogene activity (as marked by “poor-prognosis” signature expression) may be necessary for the translocation of poor-outcome human breast tumors to distant sites.
Date issued
2010-02Department
Koch Institute for Integrative Cancer Research at MITJournal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Wolfer, A., B. S. Wittner, D. Irimia, R. J. Flavin, M. Lupien, R. N. Gunawardane, C. A. Meyer, et al. “MYC Regulation of a ‘Poor-Prognosis’ Metastatic Cancer Cell State.” Proceedings of the National Academy of Sciences 107, no. 8 (February 23, 2010): 3698–3703.
Version: Final published version
ISSN
0027-8424
1091-6490